See other companies on Welcome to the Jungle
Click Therapeutics
Developing software as prescription treatments
- 101-200 employees
- Healthcare
- SaaS
- Biotechnology
- Chinatown, New York, NY
Jump to section
Company mission
To deliver safe and effective digital treatments to patients in need.
Our take
Prescription medical treatments have historically been comprised only of pharmaceutical drugs and therapies, but digital therapeutics present an effective and low-cost alternative. With treatment provided through a clinically trialled app, these solutions have found success in tackling major medical issues such as type 2 diabetes, depression and and smoking.
Click Therapeutics is one company working in this field, providing prescription software as a treatment for patients with unmet and high-burden needs such as chronic pain, major depressive disorder and migraines. There are other companies working in this area such as OurPath, Soma, and Ieso, but the global digital therapeutics market is estimated to be worth up to $18 billion by 2027 and is still largely untapped, leaving plenty of room to grow.
Click Therapeutics has raised funding through several investment rounds and debt financing. It is using this capital to accelerate the development of its products and further improve the performance of its platform. As the efficacy of digital therapeutics becomes more widely-known, Click Therapeutics is in a strong position to grow.
Freddie
Company Specialist at Welcome to the Jungle
Benefits
- Annual performance-based cash bonus
- Choice of Mac, Windows, or Linux equipment
- Life insurance and disability benefits
- Monthly catered lunches
- Sponsored company events
- Generous paid parental leave
- Unlimited PTO
- Stock options
- Flexible Spending Accounts
- 401(k) matching
- Comprehensive medical benefits through Aetna
- Open vacation policy
- Commuter subsidies
- Free, unlimited office snacks and beverages
Company values
- Patients first
- Act with integrity
- Expect excellence
- No jerks
- Own it
- Make work fun
Funding (last 2 of 9 rounds)
Oct 2021
$52m
SERIES B
Oct 2018
$19m
EARLY VC
Total funding: $96.6m
Leadership
David Benshoof Klein
(CEO)Experience as Managing Director of Opus Point Partners from 2007 to 2012. Senior Consultant of Pfizer from 2012 to 2014.